https://www.onclive.com/view/inca33890-plus-soc-elicits-responses-and-is-tolerable-across-in-first--and-third-line-mss-crc2026-10-24T17:00:00Z2026-10-24T17:00:00Z https://www.onclive.com/view/dr-feldman-on-ixotatug-vedotin-in-heavily-pretreated-recurrent-germ-cell-tumors2026-10-24T16:58:18.413Z2026-10-24T16:58:18.413Z https://www.onclive.com/view/durvalumab-plus-bcg-improves-dfs-in-papillary-only-bcg-naive-high-risk-nmibc-in-potomac2026-10-24T16:53:46.503Z2026-10-24T16:53:46.503Z https://www.onclive.com/view/durvalumab-plus-olaparib-improves-os-in-advanced-endometrial-cancer2026-10-24T16:38:35.396Z2026-10-24T16:38:35.396Z https://www.onclive.com/view/perioperative-enfortumab-vedotin-plus-pembrolizumab-does-not-compromise-qol-in-cisplatin-eligible-mibc2026-10-24T16:05:05.423Z2026-10-24T16:05:05.423Z https://www.onclive.com/view/ctdna-analyses-from-crown-identify-predictors-of-early-progression-with-first-line-lorlatinib2026-10-24T15:24:23.245Z2026-10-24T15:24:23.245Z https://www.onclive.com/view/dr-enke-on-interim-safety-data-for-lutetium-lu-177-vipivotide-tetraxetan-retreatment-in-mcrpc2026-10-24T14:53:39.100Z2026-10-24T14:53:39.100Z https://www.onclive.com/view/t-dxd-followed-by-thp-elicits-deep-mri-responses-in-her2-early-breast-cancer2026-10-24T14:05:10.321Z2026-10-24T14:05:10.321Z https://www.onclive.com/view/final-os-postmonarch-favors-abemaciclib-plus-fulvestrant-hr-her2-advanced2026-10-24T13:58:02.712Z2026-10-24T13:58:02.712Z https://www.onclive.com/view/incb123667-plus-bevacizumab-shows-antitumor-activity-in-recurrent-epithelial-ovarian-cancer2026-10-24T13:25:54.532Z2026-10-24T13:25:54.532Z https://www.onclive.com/view/atirmociclib-plus-fulvestrant-improves-pfs-hr-her2-advanced-breast-cancer2026-10-24T12:44:30.339Z2026-10-24T12:44:30.339Z https://www.onclive.com/view/panku-breast01-iza-bren-improves-pfs-vs-chemotherapy-pretreated-hr-her2-advanced-breast-cancer2026-10-24T12:18:59.027Z2026-10-24T12:18:59.027Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-10-18-20262026-10-24T12:00:00Z2026-10-24T12:00:00Z https://www.onclive.com/view/ixotatug-vedotin-elicits-responses-in-heavily-pretreated-recurrent-germ-cell-tumors2026-10-24T11:55:59.175Z2026-10-24T11:55:59.175Z https://www.onclive.com/view/keynote-b15-ctdna-analysis-perioperative-ev-pembrolizumab-higher-ctdna-clearance-mibc2026-10-23T23:36:28.737Z2026-10-23T23:36:28.737Z https://www.onclive.com/view/pembrolizumab-plus-chemo-misses-efs-end-point-in-cisplatin-eligible-mibc2026-10-23T23:00:00Z2026-10-23T23:00:00Z https://www.onclive.com/view/sacituzumab-govitecan-triplet-elicits-durable-responses-in-treatment-naive-metastatic-urothelial-cancer2026-10-23T22:50:46.714Z2026-10-23T22:50:46.714Z https://www.onclive.com/view/surufatinib-plus-serplulimab-and-chemo-shows-activity-in-first-line-extrapulmonary-nec2026-10-23T20:41:23.424Z2026-10-23T20:41:23.424Z https://www.onclive.com/view/ad-hoc-analysis-supports-contributions-of-both-enfortumab-vedotin-and-pembrolizumab-in-cisplatin-ineligible-mibc2026-10-23T20:36:40.500Z2026-10-23T20:36:40.500Z https://www.onclive.com/view/adjuvant-giredestrant-preserves-qol-with-sustained-tolerability-in-er-her2-early-breast-cancer2026-10-23T18:40:00Z2026-10-23T18:40:00Z https://www.onclive.com/view/arcotatug-tavatecan-improves-survival-in-cldn18-2-advanced-gastric-or-gej-adenocarcinoma2026-10-23T17:19:43.517Z2026-10-23T17:19:43.517Z https://www.onclive.com/view/adding-uv1-vaccine-to-olaparib-durvalumab-maintenance-misses-pfs-end-point-in-brca-wild-type-recurrent-ovarian-cancer2026-10-23T17:11:11.668Z2026-10-23T17:11:11.668Z https://www.onclive.com/view/perioperative-nivolumab-plus-neoadjuvant-chemotherapy-misses-co-primary-end-points-in-mibc2026-10-23T16:10:50.484Z2026-10-23T16:10:50.484Z https://www.onclive.com/view/roswell-park-team-finds-potential-key-to-chemotherapy-resistance-in-triple-negative-breast-cancer2026-10-23T16:00:00Z2026-10-23T16:00:00Z https://www.onclive.com/view/daraxonrasib-improves-os-across-ras-genotype-and-treatment-subgroups-in-previously-treated2026-10-23T15:59:16.865Z2026-10-23T15:59:16.865Z https://www.onclive.com/view/teclistamab-monotherapy-wins-eu-approval-for-r-r-myeloma-after-at-least-1-prior-therapy2026-10-23T15:17:26.691Z2026-10-23T15:17:26.691Z https://www.onclive.com/view/ubamatamab-activity-in-recurrent-low-grade-serous-ovarian-cancer2026-10-23T12:00:00Z2026-10-23T12:00:00Z https://www.onclive.com/view/onclive-weekly-news-quiz-10-23-2026-did-you-miss-crucial-rectal-bladder-and-kidney-cancer-updates-2026-10-23T12:00:00Z2026-10-23T12:00:00Z https://www.onclive.com/view/polls-reveal-top-picks-for-lung-cancer-abstracts-of-interest-at-esmo-20262026-10-23T11:55:00Z2026-10-23T11:55:00Z https://www.onclive.com/view/poll-results-highlight-gynecologic-cancer-abstracts-of-interest-at-esmo-20262026-10-23T11:10:00Z2026-10-23T11:10:00Z https://www.onclive.com/view/dr-nghiemphu-on-how-the-nccn-inclusion-of-brigatinib-expands-access-for-nf2-related-schwannomatosis2026-10-23T00:00:00Z2026-10-23T00:00:00Z https://www.onclive.com/view/her2-mcrc-treatment-sequencing-favors-tucatinib-plus-trastuzumab-before-t-dxd2026-10-22T19:45:00Z2026-10-22T19:45:00Z https://www.onclive.com/view/fda-grants-full-approval-to-pembrolizumab-for-unresectable-metastatic-tmb-h-solid-tumors2026-10-22T19:15:03.587Z2026-10-22T19:15:03.587Z https://www.onclive.com/view/sbe303-receives-fda-fast-track-designation-in-pretreated-urothelial-cancer2026-10-22T17:56:52.631Z2026-10-22T17:56:52.631Z https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-onvansertib-for-chronic-myelomonocytic-leukemia2026-10-22T17:05:57.456Z2026-10-22T17:05:57.456Z https://www.onclive.com/view/roginolisib-demonstrates-preliminary-activity-in-metastatic-uveal-melanoma2026-10-22T16:29:26.139Z2026-10-22T16:29:26.139Z https://www.onclive.com/view/ut-md-anderson-s-albert-koong-and-katy-rezvani-elected-to-the-national-academy-of-medicine2026-10-22T16:00:00Z2026-10-22T16:00:00Z https://www.onclive.com/view/dr-oberstein-on-the-rationale-for-evaluating-the-pd-1-il-15-fusion-protein-sar445877-in-mss-crc2026-10-21T21:15:00Z2026-10-21T21:15:00Z https://www.onclive.com/view/experts-tackle-key-questions-on-cdk4-6-inhibition-across-hr-breast-cancer-settings2026-10-21T20:38:41.376Z2026-10-21T20:38:41.376Z https://www.onclive.com/view/pembrolizumab-plus-enfortumab-vedotin-earns-ec-approval-in-resectable-mibc2026-10-21T19:57:43.588Z2026-10-21T19:57:43.588Z https://www.onclive.com/view/tolerability-remains-a-trop2-directed-adc-hurdle-in-egfr-mutated-nsclc2026-10-21T19:50:00Z2026-10-21T19:50:00Z https://www.onclive.com/view/dr-sinicrope-on-crc-abstracts-to-watch-at-the-2026-esmo-congress2026-10-21T16:30:00Z2026-10-21T16:30:00Z https://www.onclive.com/view/body-composition-changes-on-ct-scans-may-help-identify-pancreatic-cancer-risk2026-10-21T16:00:00Z2026-10-21T16:00:00Z https://www.onclive.com/view/beyond-pd-l1-refining-first-line-treatment-decisions-in-metastatic-nsclc2026-10-21T15:40:00Z2026-10-21T15:40:00Z https://www.onclive.com/view/lisaftoclax-plus-acalabrutinib-received-breakthrough-therapy-designation-in-china-for-treatment-naive-cll-sll2026-10-21T14:58:00.552Z2026-10-21T14:58:00.552Z https://www.onclive.com/view/order-both-ihc-and-ngs-defining-met-alterations-and-positioning-telisotuzumab-vedotin-in-non-small-cell-lung-cancer2026-10-21T14:45:50.037Z2026-10-21T14:45:50.037Z https://www.onclive.com/view/fda-approval-of-dostarlimab-brings-potential-organ-sparing-approach-in-dmmr-locally-advanced-rectal-cancer2026-10-21T13:00:00Z2026-10-21T13:00:00Z https://www.onclive.com/view/clinical-pearls-for-multiple-myeloma-management2026-10-21T12:05:00Z2026-10-21T12:05:00Z https://www.onclive.com/view/combination-strategies-and-sequencing-in-relapsed-refractory-multiple-myeloma2026-10-21T12:05:00Z2026-10-21T12:05:00Z https://www.onclive.com/view/next-generation-ctla-4-therapy-in-squamous-nsclc2026-10-21T12:05:00Z2026-10-21T12:05:00Z https://www.onclive.com/view/delivering-therapy-beyond-the-trial-setting2026-10-21T12:05:00Z2026-10-21T12:05:00Z https://www.onclive.com/view/emerging-post-immunotherapy-strategies-in-renal-cell-carcinoma2026-10-21T12:05:00Z2026-10-21T12:05:00Z https://www.onclive.com/view/monitoring-immune-toxicities-in-squamous-nsclc2026-10-21T12:00:00Z2026-10-21T12:00:00Z https://www.onclive.com/view/treatment-sequencing-in-multiple-myeloma2026-10-21T12:00:00Z2026-10-21T12:00:00Z https://www.onclive.com/view/administering-axatilimab-from-order-to-observation2026-10-21T12:00:00Z2026-10-21T12:00:00Z https://www.onclive.com/view/sequencing-targeted-therapy-in-advanced-renal-cell-carcinoma2026-10-21T12:00:00Z2026-10-21T12:00:00Z https://www.onclive.com/view/access-community-implementation-and-guideline-updates-in-relapsed-refractory-multiple-myeloma2026-10-21T12:00:00Z2026-10-21T12:00:00Z https://www.onclive.com/view/her2-maintenance-therapy-approvals-and-innovative-brain-metastasis-care-reshape-breast-cancer-management2026-10-20T21:35:00Z2026-10-20T21:35:00Z https://www.onclive.com/view/treatment-tailoring-and-weighing-alternative-formulations-support-optimal-tki-deployment-in-cml2026-10-20T20:40:45.232Z2026-10-20T20:40:45.232Z https://www.onclive.com/view/casdatifan-demonstrates-activity-in-advanced-clear-cell-rcc2026-10-20T19:27:15.320Z2026-10-20T19:27:15.320Z https://www.onclive.com/view/dr-margol-on-an-optimal-diagnostic-workflow-in-pediatric-low-grade-glioma2026-10-20T17:25:00Z2026-10-20T17:25:00Z https://www.onclive.com/view/qtx3034-plus-cetuximab-receives-fda-fast-track-designation-in-kras-g12d-mutated-crc2026-10-20T16:05:00Z2026-10-20T16:05:00Z https://www.onclive.com/view/mimivax-and-roswell-park-announce-results-from-phase-2b-survive-trial-of-survaxm-in-newly-diagnosed-glioblastoma2026-10-20T16:00:00Z2026-10-20T16:00:00Z https://www.onclive.com/view/pd-l1-level-histology-and-toxicity-profile-guide-frontline-ici-selection-in-nsclc2026-10-20T15:43:52.842Z2026-10-20T15:43:52.842Z https://www.onclive.com/view/fda-grants-fast-track-designation-to-mc001-in-pancreatic-cancer2026-10-20T15:11:47.391Z2026-10-20T15:11:47.391Z https://www.onclive.com/view/nccn-guidelines-upgrade-cosibelimab-to-category-2a-for-locally-advanced-cutaneous-squamous-cell2026-10-20T14:14:23.111Z2026-10-20T14:14:23.111Z https://www.onclive.com/view/frontline-choice-with-chronic-kidney-disease-and-prior-thrombosis2026-10-20T12:05:00Z2026-10-20T12:05:00Z https://www.onclive.com/view/bone-predominant-egfr-l858r-nsclc-with-multiple-comorbidities2026-10-20T12:00:00Z2026-10-20T12:00:00Z https://www.onclive.com/view/t-dxd-and-t-dm1-selection-in-her2-positive-early-breast-cance2026-10-20T12:00:00Z2026-10-20T12:00:00Z https://www.onclive.com/view/vilamakitug-meets-os-threshold-in-phase-1-2-refractory-mcrc-trial2026-10-19T23:00:00Z2026-10-19T23:00:00Z https://www.onclive.com/view/dr-cercek-on-the-fda-approval-of-dostarlimab-for-dmmr-msi-h-locally-advanced-rectal-cancer2026-10-19T21:00:49.884Z2026-10-19T21:00:49.884Z https://www.onclive.com/view/weigh-benefit-against-burden-defining-lurbinectedin-s-role-in-a-shifting-small-cell-lung-cancer-landscape2026-10-19T20:50:00Z2026-10-19T20:50:00Z https://www.onclive.com/view/dr-warren-on-the-goal-of-the-4ward-trial-evaluating-mavorixafor-in-chronic-neutropenia2026-10-19T20:40:46.621Z2026-10-19T20:40:46.621Z https://www.onclive.com/view/fda-clears-tumorsight-risk-an-mri-derived-ai-recurrence-tool-for-hr-her2-breast-cancer2026-10-19T19:20:00Z2026-10-19T19:20:00Z https://www.onclive.com/view/fda-approves-dostarlimab-for-dmmr-msi-h-locally-advanced-rectal-cancer2026-10-19T16:48:09.830Z2026-10-19T16:48:09.830Z https://www.onclive.com/view/fda-accepts-nda-for-ugn-103-in-recurrent-low-grade-intermediate-risk-nmibc2026-10-19T16:06:16.918Z2026-10-19T16:06:16.918Z https://www.onclive.com/view/newly-established-cancer-leadership-roles-bring-promise-to-the-future-of-research-and-care2026-10-19T16:00:00Z2026-10-19T16:00:00Z https://www.onclive.com/view/japan-approves-on-body-injector-for-subcutaneous-isatuximab-in-multiple-myeloma2026-10-19T14:02:43.477Z2026-10-19T14:02:43.477Z https://www.onclive.com/view/sunvozertinib-for-egfr-exon-20-insertion-nsclc-across-pretreated-and-first-line-settings2026-09-30T17:36:57.286Z2026-10-19T13:40:11.601Z https://www.onclive.com/view/surgery-vs-systemic-therapy-in-diffuse-tgct2026-10-19T12:05:00Z2026-10-19T12:05:00Z https://www.onclive.com/view/recognizing-tgct-and-shifting-referral-patterns2026-10-19T12:00:00Z2026-10-19T12:00:00Z https://www.onclive.com/view/selecting-first-line-therapy-and-prioritizing-biomarkers-in-her2-positive-gea2026-10-19T12:00:00Z2026-10-19T12:00:00Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-10-122026-10-18T12:00:00Z2026-10-18T12:00:00Z https://www.onclive.com/view/early-phase-inca33890-data-lay-the-foundation-for-phase-3-combination-research-in-mss-crc2026-10-18T10:00:00Z2026-10-18T10:00:00Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-10-112026-10-17T14:22:13.579Z2026-10-17T14:22:13.579Z https://www.onclive.com/view/cemiplimab-receives-chmp-recommendation-in-multiple-cancer-types2026-10-17T10:00:00Z2026-10-17T10:00:00Z https://www.onclive.com/view/fda-approval-insights-first-line-maintenance-tucatinib-trastuzumab-pertuzumab-in-advanced-her2-breast-cancer2026-10-16T19:30:00Z2026-10-16T19:30:00Z https://www.onclive.com/view/volga-dasl-hicap-data-highlight-key-genitourinary-cancer-presentations-arriving-at-esmo-20262026-10-16T19:20:00Z2026-10-16T19:20:00Z https://www.onclive.com/view/neoadjuvant-nautika1-data-broad-molecular-profiling-and-clinical-pearls2026-10-16T18:38:45.230Z2026-10-16T18:38:45.230Z https://www.onclive.com/view/first-line-data-from-amigo-1-and-copernicus-egfr-result-in-central-nervous-system-involvement-and-kras-g12c-in-practice2026-10-16T18:27:22.053Z2026-10-16T18:27:22.053Z https://www.onclive.com/view/the-egfr-result-at-progression-and-the-updated-harmoni-overall-survival-analysis2026-10-16T18:23:09.459Z2026-10-16T18:23:09.459Z https://www.onclive.com/view/large-scale-study-advances-detection-of-dna-mutations-across-the-human-genome2026-10-16T16:00:00Z2026-10-16T16:00:00Z https://www.onclive.com/view/frequently-asked-questions-on-breast-cancer-patient-support-self-advocacy-and-survivorship2026-10-16T15:40:00Z2026-10-16T15:40:00Z https://www.onclive.com/view/talquetamab-plus-daratumumab-earns-chmp-backing-in-r-r-myeloma2026-10-16T15:24:26.256Z2026-10-16T15:24:26.256Z https://www.onclive.com/view/onclive-weekly-news-quiz-10-16-2026-bladder-neuroendocrine-pancreatic-liver-cancer-updates2026-10-16T14:47:35.162Z2026-10-16T14:47:35.162Z https://www.onclive.com/view/looking-ahead-immunotherapy-s-role-unmet-needs-and-what-the-panel-is-watching2026-10-16T12:05:00Z2026-10-16T12:05:00Z https://www.onclive.com/view/exon-20-insertions-approved-options-new-data-and-the-oral-agent-landscape2026-10-16T12:00:00Z2026-10-16T12:00:00Z https://www.onclive.com/view/refined-adc-development-helps-weigh-biomarker-based-decisions-and-treatment-sequencing-in-gynecologic-cancers2026-10-15T21:03:40.556Z2026-10-15T21:03:40.556Z https://www.onclive.com/view/stay-ahead-of-esmo-2026-see-what-lung-cancer-experts-are-prioritizing2026-10-15T21:00:00Z2026-10-15T21:00:00Z https://www.onclive.com/view/analysis-associates-lifileucel-with-low-rates-of-post-discharage-severe-traes-and-hospital-readmission-in-advanced-melanoma2026-10-15T19:36:47.284Z2026-10-15T19:36:47.284Z